scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199903113401001 |
P698 | PubMed publication ID | 10072408 |
P2093 | author name string | Mason AC | |
El-Serag HB | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | United States of America | Q30 |
hepatocellular carcinoma | Q1148337 | ||
P304 | page(s) | 745-750 | |
P577 | publication date | 1999-03-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Rising incidence of hepatocellular carcinoma in the United States | |
P478 | volume | 340 |
Q49097732 | (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study |
Q39233799 | 14-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation |
Q40585291 | 15-Deoxy-delta12,14-prostaglandin J2, a ligand for peroxisome proliferators-activated receptor-gamma, induces apoptosis in human hepatoma cells |
Q30496696 | 3-D modeling of the thermal coagulation necrosis induced by an interstitial ultrasonic transducer |
Q42857965 | A Life-Saving Cancer: More on the Double Whammy |
Q43484980 | A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria |
Q37270468 | A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells |
Q34024535 | A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma |
Q27473000 | A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades |
Q35068672 | A highly sensitive x-ray imaging modality for hepatocellular carcinoma detection in vitro |
Q34611637 | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas |
Q33581156 | A novel biomarker TERTmRNA is applicable for early detection of hepatoma |
Q33265633 | A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma |
Q50115050 | A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells |
Q40351843 | A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. |
Q46574374 | A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma |
Q38428175 | A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). |
Q39922106 | A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. |
Q44930012 | A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma |
Q33343204 | A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma |
Q83311261 | A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma |
Q49467808 | A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma |
Q24544663 | A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma |
Q46081574 | A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. |
Q40224948 | A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma |
Q36859211 | A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. |
Q41439920 | A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma |
Q43292659 | A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. |
Q44442215 | A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma |
Q35032965 | A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
Q34126254 | A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection |
Q104795075 | ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway |
Q55035513 | AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. |
Q37488688 | Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. |
Q38337088 | Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors |
Q30448846 | Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma |
Q36905691 | Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma |
Q45873421 | Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. |
Q45880013 | Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice |
Q40005823 | Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes |
Q86193896 | Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion |
Q37002609 | Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma |
Q75338998 | Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria |
Q37122717 | Advances in experimental and translational research in the treatment of hepatocellular carcinoma |
Q39917877 | Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention |
Q34359674 | Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma |
Q38161848 | After the cure: management of HCV after achievement of SVR. |
Q44135489 | Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy |
Q34575223 | Alcohol and hepatitis C. |
Q34170359 | Alcohol-induced liver disease |
Q40707188 | Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. |
Q91617824 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized co |
Q35976258 | Alopecia: a common paraneoplastic manifestation of cholangiocarcinoma in humans and animals |
Q36595263 | Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. |
Q37246570 | Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma |
Q35231839 | Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume |
Q44088366 | Altered androgen metabolism eventually leads hepatocellular carcinoma to an impaired hormone responsiveness |
Q58700934 | Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials |
Q37665692 | Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study |
Q34463052 | An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus |
Q50710892 | An epidemiologic study of hepatocellular carcinoma in Canada. |
Q33391857 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. |
Q42131309 | An unusual initial presentation of hepatocellular carcinoma as a sellar mass. |
Q34035767 | Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection |
Q37729493 | Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines |
Q28344359 | Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors |
Q37364223 | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
Q88574991 | Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis |
Q35780838 | Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival |
Q39036885 | Approach to Solid Liver Masses in the Cirrhotic Patient |
Q37246194 | Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma |
Q39503929 | Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production |
Q94314421 | Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas |
Q35776195 | Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study |
Q33833557 | Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis |
Q33946441 | Biological impact of geometric uncertainties: what margin is needed for intra-hepatic tumors? |
Q28533447 | Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species |
Q57945502 | Blue green algal (cyanobacterial) toxins, surface drinking water, and liver cancer in Florida |
Q36920698 | Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept |
Q40359283 | Brain metastases from hepatocellular carcinoma in US patients |
Q37461714 | Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker |
Q36690763 | Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis |
Q26770014 | CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review |
Q36324498 | CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function |
Q34544245 | CT in hepatic cirrhosis and chronic hepatitis |
Q34681040 | CT perfusion of the liver: principles and applications in oncology |
Q37072699 | CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial. |
Q54999032 | CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. |
Q37797702 | Cancer Epigenome |
Q33386598 | Cancer biomarker AKR1B10 and carbonyl metabolism. |
Q34402117 | Cancer burden in the year 2000. The global picture |
Q45966861 | Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. |
Q80510550 | Cancers of the large bowel and hepatobiliary tract |
Q81086290 | Cancers of the large bowel and hepatobiliary tract |
Q33295308 | Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum |
Q39700274 | Case-control study of the RFA therapeutic effect of newly developed 4D US and conventional 2D US. |
Q35545730 | Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells |
Q53487540 | Causes of death in patients with unresectable hepatocellular carcinoma. |
Q37249594 | Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma |
Q75339016 | Challenging choices: liver transplantation for hepatocellular carcinoma |
Q37278046 | Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. |
Q36179782 | Changes in survival patterns in urban Chinese patients with liver cancer |
Q50744502 | Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. |
Q33962674 | Changing international trends in mortality rates for liver, biliary and pancreatic tumours |
Q54462115 | Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients. |
Q64232007 | Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea |
Q37262038 | Characteristics of common solid liver lesions and recommendations for diagnostic workup |
Q41518564 | Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma |
Q80114603 | Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles |
Q38391223 | Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial |
Q78418406 | Chemoembolization for hepatocellular carcinoma: where does the truth lie? |
Q45737041 | Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus |
Q26772302 | Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents |
Q35101365 | Chemopreventive strategies in hepatocellular carcinoma |
Q34067946 | Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
Q42457047 | Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. |
Q78690345 | Cholangiocarcinoma: the "other" liver cancer on the rise |
Q77129344 | Chronic Hepatitis C |
Q34137291 | Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit |
Q44767670 | Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics |
Q37278061 | Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies |
Q35628134 | Chronic hepatitis C in African Americans and other minority groups |
Q37148328 | Chronic hepatitis C virus (HCV) disease burden and cost in the United States |
Q44759300 | Chronic liver disease mortality in the United States, 1990-1998. |
Q33746278 | Cirrhosis of liver. |
Q52087746 | Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. |
Q35163337 | Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans |
Q35289603 | Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma |
Q43686220 | Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? |
Q36016030 | Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma |
Q89750132 | Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: |
Q84273456 | Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma |
Q44038010 | Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. |
Q34357073 | Clinical implications of cancer stem cell biology in hepatocellular carcinoma |
Q29616866 | Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver |
Q85283149 | Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma |
Q51643325 | Clinical trials and their translation in hepatology: past, present, and future. |
Q42278956 | Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population |
Q45739008 | Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients--experience from an Australian hepatobiliary unit |
Q45036838 | Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma |
Q35010409 | Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma |
Q36612365 | Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma |
Q31157318 | Cluster of liver cancer and immigration: a geographic analysis of incidence data for Ontario 1998-2002. |
Q53089521 | Combination of sulfamethoxazole and selenium in anticancer therapy: a novel approach. |
Q82742558 | Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma |
Q40339271 | Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion |
Q38197831 | Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis |
Q36638136 | Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma |
Q34093354 | Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model |
Q36519015 | Comparative and integrative functional genomics of HCC. |
Q38353727 | Comparative effectiveness in hepatic malignancies |
Q33728023 | Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease |
Q51703108 | Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? |
Q42143353 | Comparison between the treatment area of electrode used for radiofrequency ablation of liver cancer focusing on 15G cooled-tip and CWT electrode |
Q40553758 | Comparison of Clinicopathologic Characteristics and Outcomes After Resection in Patients With Hepatocellular Carcinoma Treated in the United States, France, and Japan |
Q42999544 | Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis |
Q35942016 | Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis |
Q79925712 | Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma |
Q81577003 | Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells |
Q44447714 | Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute |
Q30483902 | Computer-aided diagnosis for the classification of focal liver lesions by use of contrast-enhanced ultrasonography |
Q34522010 | Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. |
Q41659507 | Contemporary strategies in the management of hepatocellular carcinoma |
Q34617414 | Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). |
Q30478164 | Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma |
Q56985572 | Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis |
Q35658940 | Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. |
Q50710789 | Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. |
Q45525964 | Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis |
Q40780468 | Cost-effectiveness of treatments for chronic hepatitis C. |
Q34539948 | Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? |
Q89474143 | Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update |
Q92276626 | Current and Future Systemic Therapies for Hepatocellular Carcinoma |
Q34623730 | Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review |
Q38158226 | Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea |
Q37072518 | Current management of advanced hepatocellular carcinoma |
Q84121761 | Current management of hepatocellular cancer |
Q57756921 | Current management of liver cancer |
Q43093342 | Current management strategy of hepatocellular carcinoma |
Q34982945 | Current perspectives in cancer proteomics |
Q34593957 | Current status of liver transplantation for hepatocellular cancer |
Q40014368 | Current status of therapy for hepatocellular carcinoma |
Q33951473 | Current therapy for chronic hepatitis C. |
Q79424117 | Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States |
Q40275006 | Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma |
Q39047929 | DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. |
Q36382856 | Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells |
Q82392060 | Deaths on the liver transplant waiting list: an analysis of competing risks |
Q37431536 | Decoding human liver cancer signatures. |
Q35870767 | Decreased PCSK9 expression in human hepatocellular carcinoma. |
Q34958488 | Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity |
Q37714088 | Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C |
Q53121903 | Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. |
Q49202205 | Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway |
Q73234099 | Delayed liquid gastric emptying in patients with hepatocellular carcinoma |
Q30738437 | Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. |
Q37278212 | Demographics of a large cohort of urban chronic hepatitis C patients |
Q28201418 | Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients |
Q36577658 | Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells |
Q33410061 | Detection of hepatocellular carcinoma using glycomic analysis |
Q47441957 | Detection of identical Helicobacter DNA in the stomach and in the non-cirrhotic liver of patients with hepatocellular carcinoma |
Q52672723 | Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. |
Q30488488 | Detoxification of Aflatoxin-Contaminated Maize by Neutral Electrolyzed Oxidizing Water. |
Q36746850 | Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma |
Q37380388 | Development of novel treatments for hepatitis C. |
Q37015632 | Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma |
Q34555816 | Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study |
Q34547411 | Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma |
Q34098835 | Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring |
Q80850379 | Diagnosis of hepatocellular carcinoma |
Q39213771 | Diagnosis of hepatoma using grayscale and Doppler ultrasound in patients with chronic liver disease |
Q37577551 | Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. |
Q35270302 | Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma |
Q33788058 | Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States |
Q79823799 | Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening |
Q35052730 | Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. |
Q38768256 | Disease monitoring of hepatocellular carcinoma through metabolomics |
Q34422414 | Disparities in Liver Cancer Incidence by Nativity, Acculturation, and Socioeconomic Status in California Hispanics and Asians |
Q36806996 | Disparities in liver transplantation before and after introduction of the MELD score |
Q35740123 | Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer |
Q27489928 | Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma |
Q46059193 | Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma |
Q34083775 | Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? |
Q74402233 | Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? |
Q30426959 | Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma? |
Q24685704 | Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma |
Q40175472 | Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. |
Q45323756 | Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study |
Q43078745 | Drug therapy: sorafenib |
Q34391996 | Drug treatment of the complications of cirrhosis in the older adult |
Q24187663 | Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma |
Q24202061 | Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma |
Q35207490 | Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection |
Q58236150 | Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience |
Q33280446 | Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system |
Q36348796 | Early liver cancer: concepts, diagnosis, and management |
Q35736527 | Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort |
Q33742856 | Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma |
Q40279496 | Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population |
Q40950784 | Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection |
Q37478899 | Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver |
Q28361953 | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial |
Q54616826 | Effect of sorafenib on murine liver regeneration. |
Q33977186 | Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients |
Q43138169 | Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice |
Q34583094 | Effects and mechanisms of silibinin on human hepatoma cell lines |
Q41910185 | Effects of blueberries on migration, invasion, proliferation, the cell cycle and apoptosis in hepatocellular carcinoma cells |
Q53102584 | Effects of implementing an "enhanced recovery after surgery" program on patients undergoing resection of hepatocellular carcinoma. |
Q37002698 | Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma |
Q46468589 | Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation. |
Q43031055 | Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone |
Q34017814 | Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study |
Q90602411 | Elastic Net Constrained Stereotype Logit Model for Ordered Categorical Data |
Q81342006 | Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival |
Q34533357 | Embolisation of cancer: what is the evidence? |
Q28391490 | Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathways |
Q42701066 | Endoscopic Ultrasound -guided Fine-Needle Aspiration of a Portal Vein Thrombus to Aid in the Diagnosis and Staging of Hepatocellular Carcinoma. |
Q24628144 | Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma |
Q90458437 | Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo |
Q34076490 | Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells |
Q40600354 | Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway |
Q36365466 | Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation. |
Q37241377 | Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States |
Q34527770 | Epidemiology and clinical presentation of hepatocellular carcinoma |
Q73541726 | Epidemiology of hepatocellular carcinoma |
Q78726781 | Epidemiology of hepatocellular carcinoma |
Q80426424 | Epidemiology of hepatocellular carcinoma in Bas-Rhin: analysis of all incident cases from 1990 to 1999 |
Q80066047 | Epidemiology of hepatocellular carcinoma in Finistère. Prospective study from June 2002 to May 2003 |
Q36519002 | Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity |
Q36411144 | Epigenetic instability and chromosomal instability in hepatocellular carcinoma |
Q92001987 | Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis |
Q43049278 | Epstein-Barr virus and human hepatocellular carcinoma |
Q30831603 | Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. |
Q41690819 | Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome |
Q36415612 | Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. |
Q73073538 | Estimating future hepatitis C morbidity, mortality, and costs in the United States |
Q35171592 | Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. |
Q80463938 | Ethnic differences in hepatocellular carcinoma: implications for liver transplantation |
Q87620289 | Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy |
Q34394471 | Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. |
Q37290714 | Evolving therapies in the treatment of hepatocellular carcinoma |
Q42496570 | Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma |
Q28191190 | Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma |
Q44794722 | Experiences in liver transplantation for hepatocellular carcinoma |
Q40036988 | Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo |
Q35011207 | Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma |
Q43889420 | Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro |
Q43585856 | Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma |
Q54215487 | Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance. |
Q43076650 | Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma |
Q33648955 | Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma |
Q28481696 | Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway |
Q35597331 | Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation. |
Q81120947 | Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection |
Q43924482 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy |
Q42877691 | Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma |
Q37613015 | Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients |
Q35195272 | Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C |
Q58108213 | Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma |
Q35699313 | Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma |
Q36363383 | Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. |
Q30235178 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
Q35207733 | Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians |
Q28550036 | Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma |
Q27490242 | Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma |
Q37790070 | Gene signatures in hepatocellular carcinoma (HCC). |
Q40644810 | Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. |
Q35208038 | Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact |
Q45865909 | Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene |
Q27487515 | Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma |
Q34624434 | Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis |
Q42258048 | Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. |
Q41918713 | Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma |
Q34764430 | Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation |
Q37500885 | Genomic profiling of liver cancer |
Q33399464 | Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma |
Q44041035 | Geographic variation within the United States in the incidence of hepatocellular carcinoma |
Q37466205 | Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. |
Q27860799 | Global epidemiology of hepatitis C virus infection |
Q36002022 | Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure. |
Q50176311 | Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells |
Q38366329 | Glycosylation and liver cancer |
Q36124126 | Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma |
Q40977209 | Graph cut liver segmentation for interstitial ultrasound therapy |
Q34544239 | Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention |
Q50472148 | Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. |
Q53652121 | Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. |
Q34532749 | Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults |
Q81898519 | HA/GSA-Rmax ratio as a predictor of postoperative liver failure |
Q83078598 | HBV-related HCC, clinical issues and therapy |
Q30245486 | HIV, Aging, and Viral Coinfections: Taking the Long View. |
Q90423329 | HNF4α-Deficient Fatty Liver Provides a Permissive Environment for Sex-Independent Hepatocellular Carcinoma |
Q43637077 | HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice |
Q38642356 | Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model |
Q36239313 | Health care reform: how personalized medicine could help bundling of care for liver diseases |
Q37249688 | Health disparities in liver disease: Time to take notice and take action |
Q35538156 | Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. |
Q36644408 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies |
Q37352004 | Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets |
Q33344056 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases |
Q36180460 | Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis |
Q33604270 | Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma |
Q28202929 | Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes |
Q38410821 | Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma |
Q42685478 | Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria |
Q36332915 | Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality |
Q45723125 | Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma? |
Q44464287 | Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection |
Q36815013 | Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis |
Q37627088 | Hepatitis B and C in African Americans: current status and continued challenges |
Q35045196 | Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients |
Q43079078 | Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma |
Q35595027 | Hepatitis C and HIV-1 coinfection |
Q57724630 | Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients |
Q34228398 | Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma |
Q33934023 | Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system |
Q39345427 | Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling |
Q33516543 | Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers |
Q34542083 | Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. |
Q22305832 | Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies |
Q36111060 | Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma |
Q24631773 | Hepatobiliary MR imaging with gadolinium-based contrast agents |
Q34336505 | Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon |
Q64109847 | Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States |
Q26781798 | Hepatocellular Carcinoma and Liver Transplantation: State of the Art |
Q60951670 | Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis |
Q34131801 | Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting |
Q48268747 | Hepatocellular Carcinoma: Surgical Management and Evolving Therapies |
Q29615841 | Hepatocellular carcinoma |
Q57696098 | Hepatocellular carcinoma |
Q74267144 | Hepatocellular carcinoma |
Q93930900 | Hepatocellular carcinoma |
Q39027102 | Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. |
Q39754997 | Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI. |
Q35362361 | Hepatocellular carcinoma in Central Europe: prognostic features and survival |
Q35059721 | Hepatocellular carcinoma in Egypt: a single center study over a decade. |
Q35741066 | Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency |
Q44124162 | Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy |
Q75211784 | Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis |
Q34255487 | Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. |
Q36512811 | Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. |
Q34084962 | Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis |
Q36310075 | Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years |
Q53824769 | Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. |
Q83053433 | Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis |
Q37015123 | Hepatocellular carcinoma prevalence and mortality in a male state prison population |
Q48015576 | Hepatocellular carcinoma surveillance: The road ahead |
Q80448247 | Hepatocellular carcinoma with isolated left adrenal metastasis following liver transplantation |
Q34512068 | Hepatocellular carcinoma--cause, treatment and metastasis |
Q36579533 | Hepatocellular carcinoma--rising incidence, changing therapeutic strategies |
Q27489394 | Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis |
Q35507289 | Hepatocellular carcinoma: HCC |
Q78032946 | Hepatocellular carcinoma: a prime indication for living donor liver transplantation |
Q35193283 | Hepatocellular carcinoma: are we making progress? |
Q36108310 | Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review |
Q37355835 | Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics |
Q34633249 | Hepatocellular carcinoma: insight from animal models |
Q35196709 | Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? |
Q36687672 | Hepatocellular carcinoma: molecular biology and therapy |
Q36914691 | Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy |
Q34756070 | Hepatocellular carcinoma: predisposing conditions and precursor lesions |
Q35068060 | Hepatocellular carcinoma: present status and future prospects |
Q34409128 | Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. |
Q44890377 | Hepatocellular carcinoma: strategy for optimizing surgical resection, transplantation and palliation |
Q35174436 | Hepatocellular carcinoma: surgical indications and results |
Q36377949 | Hepatocellular carcinoma: therapy and prevention |
Q35628112 | Hepatocellular carcinoma: updates in primary prevention |
Q51665999 | Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. |
Q35507576 | Hepatocellular recurrence after orthotopic liver transplantation: Is combination of α-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation. |
Q40639511 | Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences |
Q30376715 | High correlation between microbubble contrast-enhanced ultrasound, magnetic resonance and histopathology in the evaluation of hepatocellular carcinoma. |
Q34500720 | High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. |
Q44746125 | High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population |
Q37565602 | High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. |
Q34156818 | Hospital-based, acute care encounters after radiofrequency ablation of hepatic tumours |
Q58703392 | Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B |
Q38083250 | Human hepatocyte carcinogenesis (review). |
Q24301818 | Human homologue of maid is a useful marker protein in hepatocarcinogenesis |
Q35103419 | Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma |
Q37131434 | Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes |
Q57634858 | Identification and characterization of CRG-L2, a new marker for liver tumor development |
Q33591504 | Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods |
Q44305778 | Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells |
Q74434735 | Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma |
Q30433998 | Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model |
Q37370024 | Image-guided percutaneous ablation therapies for hepatocellular carcinoma |
Q34922580 | Imaging evaluation of hepatocellular carcinoma |
Q80351857 | Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat |
Q80475287 | Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies |
Q33976481 | Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma |
Q34148593 | Immunopathogenesis of hepatitis C virus in the immunosuppressed host |
Q37144014 | Immunotherapy for liver tumors: present status and future prospects. |
Q35625989 | Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial |
Q53487180 | Impact of preoperative planning using virtual segmental volumetry on liver resection for hepatocellular carcinoma. |
Q43778834 | Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. |
Q43436743 | Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria |
Q35207762 | Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. |
Q37229285 | In search of liver cancer stem cells. |
Q39939752 | In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells |
Q38828541 | Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma |
Q33939214 | Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States |
Q36812718 | Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. |
Q35363829 | Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. |
Q58750606 | Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage |
Q35077956 | Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice |
Q30813397 | Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus |
Q40679375 | Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma |
Q33797399 | Increased mortality from liver cancer in England and Wales is not related to hepatitis C. |
Q53490169 | Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model. |
Q64378773 | Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization |
Q51037580 | Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. |
Q37002196 | Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics |
Q42987726 | Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population |
Q36695203 | Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha. |
Q30576918 | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
Q44071055 | Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad.AFPtk followed by ganciclovir treatment |
Q47424080 | Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors |
Q46082144 | Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation |
Q41128742 | Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma |
Q73979679 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach |
Q42168851 | Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients |
Q44286199 | Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy |
Q35177884 | International trends in primary liver cancer incidence from 1973 to 2007. |
Q40692505 | Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin |
Q33785906 | Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center |
Q35915311 | Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? |
Q61971049 | Is radiofrequency ablation an effective long-term treatment for early-stage hepatocellular carcinoma? |
Q38029966 | Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis |
Q44230423 | Is there a causal link between hepatitis B vaccination and multiple sclerosis? |
Q39580008 | Isatis indigotica induces hepatocellular cancer cell death via caspase-independent apoptosis-inducing factor translocation apoptotic pathway in vitro and in vivo. |
Q28280015 | KIAA0008 gene is associated with invasive phenotype of human hepatocellular carcinoma--a functional analysis |
Q40161488 | KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis |
Q33729947 | Knowledge and perceptions of hepatitis C infection and pesticides use in two rural villages in Egypt |
Q36349931 | Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists |
Q36296534 | Knowledge of viral hepatitis among Puerto Rican adults: implications for prevention |
Q33706739 | Lamivudine. A review of its therapeutic potential in chronic hepatitis B. |
Q33237223 | Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives |
Q43248970 | Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up |
Q34108430 | Laser ablation for small hepatocellular carcinoma. |
Q35370564 | Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives |
Q35154369 | Late recurrence of hepatocellular carcinoma after liver transplantation |
Q33823239 | Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma |
Q35435112 | Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma |
Q80673326 | Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment |
Q36917485 | Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. |
Q33903328 | Little response of cerebral metastasis from hepatocellular carcinoma to any treatments |
Q42320233 | Liver Imaging Reporting and Data System: an expert consensus statement |
Q40598063 | Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge |
Q33871866 | Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States |
Q41872601 | Liver cancer imaging: role of CT, MRI, US and PET. |
Q40730798 | Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms |
Q35621256 | Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma |
Q37347288 | Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma |
Q44136661 | Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? |
Q43148137 | Liver stem cells and molecular signaling pathways in hepatocellular carcinoma |
Q30470829 | Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. |
Q37625817 | Liver transplantation after radioembolization in a patient with unresectable HCC. |
Q24672943 | Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA |
Q58541779 | Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison |
Q78625642 | Liver transplantation for hepatocellular carcinoma: an Asian perspective |
Q39739700 | Liver transplantation for hepatocellular carcinoma: an update. |
Q39067623 | Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches |
Q36104785 | Liver transplantation for hepatocellular carcinoma: the ochsner experience |
Q77959039 | Liver transplantation in the therapy of hepatocellular carcinoma: a revision of our series |
Q33531442 | Liver tumour segmentation using contrast-enhanced multi-detector CT data: performance benchmarking of three semiautomated methods. |
Q39376301 | Liver vessels segmentation using a hybrid geometrical moments/graph cuts method. |
Q37708048 | Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison |
Q37382536 | LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384. |
Q26745962 | Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy |
Q32059980 | Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies |
Q47415758 | Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma |
Q31046676 | Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective |
Q58021730 | Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care |
Q53211913 | Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. |
Q46118329 | Long-term efficacy of percutaneous thermal ablation for patients with recurrent hepatocellular carcinoma |
Q37780114 | Long-term experience with liver transplantation for hepatocellular carcinoma |
Q45347565 | Long-term outcome of liver transplantation as treatment modality in patients with hepatocellular carcinoma in cirrhosis: a single-center experience |
Q56775925 | Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma |
Q46379731 | Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors |
Q77847343 | Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters |
Q77739119 | Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation |
Q43525135 | Longer survival in female than male with hepatocellular carcinoma |
Q34394479 | Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre |
Q37277822 | Loss of RhoGDI is a novel independent prognostic factor in hepatocellular carcinoma |
Q33785451 | Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis |
Q53304862 | MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. |
Q84152531 | MR elastography of the liver at 3 T with cine-tagging and bending energy analysis: preliminary results |
Q78073632 | MR imaging of hepatocellular carcinoma |
Q35083377 | MR imaging of liver tumors |
Q39975299 | MRI in detection of hepatocellular carcinoma (HCC). |
Q37724698 | MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. |
Q35409507 | Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74 |
Q34544251 | Magnetic resonance of focal liver lesions in hepatic cirrhosis and chronic hepatitis |
Q37247967 | Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. |
Q74475105 | Malignant liver tumors |
Q37096576 | Malignant liver tumors in South African children: a national audit |
Q26864406 | Management of "very early" hepatocellular carcinoma on cirrhotic patients |
Q26797581 | Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law |
Q29616230 | Management of hepatocellular carcinoma |
Q83816502 | Management of hepatocellular carcinoma |
Q36955647 | Management of hepatocellular carcinoma: Enlightening the gray zones. |
Q26997063 | Management of recurrent hepatocellular carcinoma after liver transplant |
Q35081063 | Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation |
Q38164705 | Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula |
Q34449667 | Mechanisms of alcohol-induced hepatocellular carcinoma |
Q38059437 | Medical therapies for hepatocellular carcinoma: a critical view of the evidence |
Q39817753 | Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines |
Q34782084 | Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. |
Q33443502 | Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma |
Q35201755 | Metastatic hepatocellular carcinoma |
Q36806323 | Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer |
Q35028814 | MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule |
Q28743220 | MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria |
Q39897190 | MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma |
Q29547523 | MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer |
Q37381107 | MicroRNAs as therapeutic targets in chemoresistance |
Q79777704 | Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin |
Q24312971 | Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis |
Q42172816 | Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma |
Q37328317 | Midkine: a novel prognostic biomarker for cancer |
Q64098595 | Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression |
Q74703072 | Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention |
Q42872868 | Models of hepatocellular carcinoma and biomarker strategy |
Q27480801 | Modulation of RANTES expression by HCV core protein in liver derived cell lines |
Q33983949 | Molecular biology of hepatitis C infection |
Q35048768 | Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? |
Q36646497 | Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum |
Q40390047 | Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. |
Q36618666 | Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis |
Q39214067 | Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro |
Q37003665 | Molecular targeted therapies in hepatocellular carcinoma |
Q42998892 | Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality |
Q35196596 | Molecular viral oncology of hepatocellular carcinoma |
Q53621195 | Monitoring serial CD4⁺ T-cell function after liver transplantation can be used to predict hepatocellular carcinoma recurrence. |
Q38935703 | Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities |
Q34922740 | Multidisciplinary management of hepatocellular carcinoma |
Q43000237 | Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse. |
Q37384682 | Multimodal approaches to the treatment of hepatocellular carcinoma |
Q54112398 | Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. |
Q57168249 | Mutations of the HFE gene in patients with hepatocellular carcinoma |
Q38296442 | N-linked glycosylation of the liver cancer biomarker GP73 |
Q28586911 | NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma |
Q35110675 | Nanomaterials for X-ray imaging: gold nanoparticle enhancement of X-ray scatter imaging of hepatocellular carcinoma |
Q28246583 | Nanotechnology: intelligent design to treat complex disease |
Q44637697 | Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation |
Q41129234 | Needle track seeding following percutaneous procedures for hepatocellular carcinoma |
Q34953308 | Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials |
Q37801938 | Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics |
Q26749329 | New advances in hepatocellular carcinoma |
Q33185268 | New interventions for liver tumors |
Q33266698 | New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples |
Q30448048 | New paradigm for management of hepatocellular carcinoma by imaging |
Q43234592 | New pharmacological developments in the treatment of hepatocellular cancer |
Q38742891 | Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model |
Q41858920 | Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model |
Q82156525 | Non-alcoholic fatty liver disease: is iron relevant? |
Q37564661 | Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention |
Q49191881 | Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas |
Q44892536 | Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy |
Q34041381 | Non-viral causes of hepatocellular carcinoma |
Q84989567 | Non-viral causes of hepatocellular carcinoma |
Q34653639 | Non-viral factors contributing to hepatocellular carcinoma |
Q37739949 | Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection |
Q33381184 | Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. |
Q32059984 | Nonsurgical treatment of hepatocellular carcinoma |
Q90682200 | Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma |
Q43153295 | Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. |
Q40607428 | Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis |
Q48120126 | Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. |
Q46161399 | Novel endothelial cell markers in hepatocellular carcinoma |
Q83412968 | Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report |
Q47547759 | Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. |
Q28073381 | Obesity-Related Digestive Diseases and Their Pathophysiology |
Q40526582 | Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus |
Q34557399 | Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines |
Q38447668 | Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis |
Q38081075 | Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes |
Q36069902 | Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study |
Q38197503 | Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells |
Q92669063 | Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma |
Q84104652 | Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil |
Q34478383 | Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center |
Q36273094 | Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. |
Q34130377 | Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma |
Q38223402 | Outcomes after surgery for spinal metastasis of colorectal origin: case series |
Q30431066 | Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation |
Q85050891 | Outcomes of non-anatomic liver resection for hepatocellular carcinoma in the patients with liver cirrhosis and analysis of prognostic factors |
Q34293799 | Over-expression of the ribosomal protein L36a gene is associated with cellular proliferation in hepatocellular carcinoma |
Q34053320 | Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis |
Q24645168 | Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma |
Q34100189 | Overexpression of tetraspanin CO-029 in hepatocellular carcinoma |
Q36824960 | Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma |
Q51378631 | PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. |
Q36330881 | PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice |
Q36441150 | Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. |
Q35122985 | Pathologic spectrum and prognostic significance of underlying liver disease in hepatocellular carcinoma |
Q44485326 | Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma |
Q33788043 | Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. |
Q45735081 | Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis |
Q36208355 | Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers |
Q46873874 | Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. |
Q43040967 | Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial |
Q24186496 | Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma |
Q31128451 | Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future |
Q33181403 | Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver |
Q34390771 | Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases |
Q81668582 | Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation |
Q24240216 | Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma |
Q24244936 | Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma |
Q53241493 | Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology. |
Q37158120 | Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma |
Q37495410 | Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer |
Q83292338 | Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma |
Q51778319 | Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. |
Q44865180 | Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma |
Q34593345 | Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma |
Q33818746 | Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial |
Q73060601 | Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma |
Q58114955 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis |
Q80992032 | Pituitary and bilateral adrenal enlargement: an unusual presentation of hepatocellular carcinoma |
Q34541065 | Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line |
Q35584655 | Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma |
Q41951864 | Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
Q34651625 | Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China |
Q44895098 | Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers |
Q40611976 | Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma |
Q89668258 | Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression |
Q45728735 | Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning |
Q79390690 | Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers |
Q35715916 | Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus |
Q36082172 | Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma |
Q44636627 | Predictors and patterns of recurrence after resection of hepatocellular carcinoma |
Q40376459 | Predictors of In-Hospital Mortality in patients with hepatocellular carcinoma and Acute Variceal bleeding |
Q45961421 | Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma |
Q45897134 | Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization |
Q37130713 | Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation |
Q28344083 | Preoperative galactose elimination capacity predicts complications and survival after hepatic resection |
Q43725941 | Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. |
Q78020869 | Preoperative predictors of survival after resection of small hepatocellular carcinomas |
Q79249978 | Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol |
Q33612167 | Present and future possibilities for early diagnosis of hepatocellular carcinoma |
Q35535968 | Presentation and outcomes of hepatocellular carcinoma patients at a western centre |
Q36550695 | Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection |
Q51969974 | Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. |
Q42557069 | Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats |
Q37196508 | Primary hepatocellular carcinoma and metabolic syndrome: An update |
Q52815167 | Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). |
Q38464518 | Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival |
Q35865620 | Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma |
Q39468081 | Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. |
Q42256081 | Profile of hepatocellular carcinoma in a tertiary care hospital in Punjab in northern India |
Q34037698 | Progenitor-derived hepatocellular carcinoma model in the rat. |
Q73076619 | Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification |
Q80059805 | Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma |
Q34061430 | Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems |
Q41497351 | Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China |
Q37178647 | Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma |
Q58811104 | Prognostic features and survival of hepatocellular carcinoma in Italy |
Q84183847 | Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy |
Q46322238 | Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy |
Q43693428 | Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma |
Q54997186 | Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. |
Q58321632 | Prognostic significance ofc-myc andAIB1 amplification in hepatocellular carcinoma |
Q40651059 | Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis |
Q35169393 | Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma |
Q92615766 | Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors |
Q36456976 | Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma |
Q40586760 | Prolylhydroxylase and procollagen type III in long-term survivors of acute lymphoblastic leukemia (ALL): a biochemical approach to HCV-related liver disease |
Q36316587 | Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients |
Q37586761 | Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma |
Q40263391 | Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma |
Q27478125 | Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection |
Q33387430 | Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ |
Q36952594 | Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma |
Q37235449 | Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. |
Q34609315 | Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. |
Q83811881 | Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma |
Q33378135 | Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma |
Q36519019 | Proteomics for the early detection and treatment of hepatocellular carcinoma |
Q37403329 | Pulmonary metastases from primary hepatocellular carcinoma in a 26-year-old patient: a case report |
Q36147024 | Quantitative assessment of washout in hepatocellular carcinoma using MRI. |
Q34544494 | RETRACTED: Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis |
Q55259186 | Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. |
Q51734417 | Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. |
Q42985436 | Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. |
Q37095472 | Racial disparity in liver disease: Biological, cultural, or socioeconomic factors |
Q46493966 | Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival |
Q34565716 | Radiation therapy for hepatocellular carcinoma: from palliation to cure |
Q36517404 | Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients |
Q24201669 | Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma |
Q83182890 | Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations |
Q36537526 | Radiofrequency ablation in patients with primary and secondary hepatic malignancies. |
Q37910079 | Radiofrequency ablation of high-grade dysplastic nodules |
Q34702909 | Radiofrequency ablation of unresectable primary liver cancer |
Q35166558 | Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials |
Q41790928 | Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis. |
Q82323058 | Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases |
Q34547772 | Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis |
Q91791927 | Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis |
Q37107230 | Radiofrequency ablation-assisted liver resection: review of the literature and our experience |
Q47111617 | Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. |
Q35164855 | Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. |
Q58022064 | Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma |
Q38186654 | Rare benign tumors of the liver: still rare? |
Q44128719 | Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria |
Q44764292 | Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. |
Q34821020 | Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players |
Q55227929 | Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. |
Q48348464 | Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma |
Q34483036 | Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma |
Q51023061 | Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. |
Q53391613 | Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors. |
Q39882641 | Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells |
Q37316228 | Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. |
Q35167394 | Reproducibility of CT perfusion parameters in liver tumors and normal liver |
Q42463320 | Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine |
Q79074915 | Resection of Hepatocellular Carcinoma in Patients Otherwise Eligible for Transplantation |
Q39001227 | Resection of T4 hepatocellular carcinomas with adjacent structures, is it justified? |
Q33974096 | Resection prior to liver transplantation for hepatocellular carcinoma |
Q37072527 | Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. |
Q30379347 | Response of MiRNA-22-3p and MiRNA-149-5p to Folate Deficiency and the Differential Regulation of MTHFR Expression in Normal and Cancerous Human Hepatocytes |
Q42199528 | Response to transarterial chemoembolization in candidates with hepatocellular carcinoma within Milan criteria does not predict post-transplant disease-free survival |
Q35903837 | Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis |
Q88177250 | Results of 15-Year Experience in Liver Transplant for Hepatocellular Carcinoma |
Q33851416 | Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis |
Q37450268 | Right adrenal metastases of hepatocarcinoma after liver transplantation: case report and literature review |
Q34099104 | Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). |
Q35543614 | Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes |
Q44903654 | Risk factors for hepatocellular carcinoma in patients with cirrhosis |
Q38737134 | Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study. |
Q36006339 | Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model |
Q80539045 | Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis |
Q41983643 | Role of free radicals in liver diseases. |
Q33866483 | Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients |
Q37132635 | Role of methionine adenosyltransferase genes in hepatocarcinogenesis |
Q41128609 | Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma |
Q37487162 | Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results |
Q31149403 | SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. |
Q24303537 | SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway |
Q40741225 | Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma |
Q46135283 | Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma |
Q37988322 | Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines |
Q42980924 | Scope of worldwide hepatitis C problem |
Q34162158 | Screening for cancer in viral hepatitis |
Q34922603 | Screening for hepatocellular carcinoma |
Q35594964 | Screening for hepatocellular carcinoma in cirrhosis |
Q35540833 | Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness |
Q30415026 | Selection for hepatic resection of colorectal liver metastases: expert consensus statement |
Q33965865 | Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease |
Q39562856 | Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. |
Q45401455 | Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy |
Q53589917 | Selective portal vein clamping for radiofrequency ablation of hepatocellular carcinoma with portal vein invasion. |
Q33248641 | Separate origins of hepatitis B virus surface antigen-negative foci and hepatocellular carcinomas in transgenic HBsAg (alb/psx) mice |
Q40264763 | Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients |
Q46682777 | Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease |
Q35098539 | Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma |
Q33640766 | Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4 |
Q35181045 | Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. |
Q102220362 | Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection |
Q86630953 | Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis |
Q36455499 | Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma |
Q37809251 | Signaling Networks in Human Hepatocarcinogenesis—Novel Aspects and Therapeutic Options |
Q28392002 | Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma |
Q46456555 | Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis |
Q39868832 | Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells |
Q39294082 | Simultaneous treatment of unresectable hepatocelluar carcinoma and hepatic artery aneurysm, case report |
Q39918641 | Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma |
Q42260669 | Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT. |
Q38719335 | Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study |
Q43194424 | Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? |
Q33590407 | Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study |
Q38207487 | Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. |
Q34861218 | Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom |
Q37441574 | Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study |
Q39952324 | Sorafenib for the treatment of unresectable hepatocellular carcinoma |
Q36680204 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review |
Q47646635 | Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study |
Q39140861 | Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling |
Q36708741 | Sorafenib: where do we go from here? |
Q40750117 | Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping |
Q35122991 | Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma |
Q33947885 | Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase |
Q47777632 | Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study |
Q33833270 | Statin efficacy in the treatment of hepatitis C genotype I. |
Q59150549 | Statins and metformin for chemoprevention of hepatocellular carcinoma |
Q87068963 | Statins for prevention of hepatocellular cancer: one step closer? |
Q37612864 | Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients |
Q58564362 | Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation |
Q40086254 | Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. |
Q36863488 | Strategies for the management of hepatocellular carcinoma |
Q81412667 | Subcutaneous tumor seeding following needle core biopsy of hepatocellular carcinoma |
Q51259014 | Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. |
Q38368535 | Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. |
Q37644935 | Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation |
Q41143523 | Suppression of the Wnt signaling pathway may contribute to the inhibition of proliferation of human hepatocellular carcinoma SMMC-7721 cells by esculetin |
Q44149115 | Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis |
Q37715129 | Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis |
Q37768894 | Surgical treatment of hepatocellular carcinoma: expert consensus statement |
Q34469509 | Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations |
Q36587304 | Surrogate markers of efficacy for medical treatment of viral hepatitis. |
Q45415812 | Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival |
Q85107768 | Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma |
Q33405646 | Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation |
Q37389331 | Survival of hepatocellular carcinoma in Puerto Rico |
Q34225706 | Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition |
Q41917123 | Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib |
Q50575290 | Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. |
Q33897458 | Symptom management in hepatocellular carcinoma |
Q36262043 | Synchronous primary breast cancer and hepatocellular carcinoma in a male patient: a case report |
Q39917875 | Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. |
Q36871557 | Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver |
Q33391168 | Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies |
Q35078725 | TP53 and liver carcinogenesis. |
Q36777331 | TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer |
Q34321927 | Temporal changes in liver cancer incidence rates in Japan: accounting for death certificate inaccuracies and improving diagnostic techniques |
Q38806970 | The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma |
Q57001209 | The Emerging Role of MicroRNAs in Hepatocellular Carcinoma |
Q60961386 | The Epigenetic Regulation of HCC Metastasis |
Q47185810 | The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population |
Q97644461 | The Loss of Masculine With Declined Serum DHT Is Associated With High Risk of Hepatocellular Carcinoma in Chinese Men |
Q33179763 | The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. |
Q28071619 | The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma |
Q38921949 | The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. |
Q46622652 | The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? |
Q47108317 | The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide |
Q37421369 | The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. |
Q82249610 | The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma |
Q34170288 | The current status of liver transplantation for primary hepatic malignancy. |
Q38526752 | The effect of fasting on PET Imaging of Hepatocellular Carcinoma. |
Q34523695 | The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil |
Q60929481 | The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer |
Q31004882 | The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours |
Q28362636 | The epidemiology of hepatitis C in a UK health regional population of 5.12 million |
Q36892181 | The epidemiology of hepatitis C infection in the United States |
Q30447686 | The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology |
Q33575717 | The global burden of cancer: priorities for prevention |
Q41928677 | The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma |
Q33365826 | The impact of new data in the treatment of advanced hepatocellular carcinoma |
Q81547801 | The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma |
Q37766943 | The importance of fatty liver disease in clinical practice |
Q33323289 | The imprint of radiofrequency in the management of hepatocellular carcinoma |
Q34617479 | The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis |
Q36473813 | The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area |
Q36082428 | The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma |
Q37854505 | The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists |
Q26777478 | The mutational landscape of hepatocellular carcinoma |
Q38503057 | The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection |
Q33945047 | The prevalence of hepatitis C virus infection in Texas: implications for future health care |
Q79756613 | The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma |
Q90476643 | The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma |
Q57560468 | The rise and fall in primary liver cancer mortality in Italy |
Q36873299 | The role of contrast-enhanced ultrasound for focal liver lesion detection: an overview |
Q45334263 | The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans |
Q35234037 | The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
Q46876312 | The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial |
Q27477845 | The science, economics, and effectiveness of combination therapy for hepatitis C |
Q45188223 | The survival and value of liver transplantation for liver carcinoma: a single-center experience |
Q26738658 | Therapeutic Strategies in HCC: Radiation Modalities |
Q33201409 | Therapeutic effect of photodynamic therapy using PAD-S31 and diode laser on human liver cancer cells |
Q50247004 | Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma |
Q36662565 | Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations |
Q50457812 | Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients. |
Q33403977 | Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma |
Q35777269 | Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study |
Q38022245 | Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). |
Q56371870 | Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis |
Q24235977 | Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma |
Q35797957 | Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study |
Q58765170 | Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
Q42379112 | Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma |
Q33929310 | Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival |
Q35207822 | Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study |
Q37155118 | Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients |
Q51766175 | Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. |
Q35085720 | Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma |
Q33998674 | Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma |
Q40428440 | Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration |
Q46497661 | Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection |
Q34630274 | Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? |
Q33635364 | Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy |
Q35833142 | Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma |
Q81154169 | Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study |
Q44724936 | Treatment modalities in patients with hepatocellular carcinoma: a retrospective series in a single institution in Mexico |
Q53648876 | Treatment of Hepatocellular Carcinoma. |
Q35739061 | Treatment of hepatocarcinoma |
Q57757025 | Treatment of hepatocellular carcinoma |
Q44888545 | Treatment of hepatocellular carcinoma in the cirrhotic liver |
Q35631429 | Treatment of hepatocellular carcinoma in the community: disparities in standard therapy |
Q41830340 | Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. |
Q38236876 | Treatment of intermediate-stage hepatocellular carcinoma |
Q47909976 | Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion |
Q37544738 | Treatment options for hepatitis C and the rationale for low response rates in African Americans |
Q83196334 | Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation |
Q43905234 | Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. |
Q46296781 | Trends in mortality from primary liver cancer in Europe |
Q24651526 | Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001 |
Q33761751 | Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma |
Q34021608 | Trends in waiting list registration for liver transplantation for viral hepatitis in the United States |
Q37800793 | Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets |
Q34605421 | Tumor vaccine against recurrence of hepatocellular carcinoma |
Q41196091 | Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus. |
Q33483712 | Twist expression promotes migration and invasion in hepatocellular carcinoma |
Q37356216 | Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma |
Q35596794 | Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study |
Q34143512 | Underutilization of therapy for hepatocellular carcinoma in the medicare population |
Q37383964 | Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. |
Q40707598 | Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome |
Q35674315 | Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? |
Q43042926 | Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions |
Q36325322 | Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma |
Q34224698 | Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples |
Q42722250 | Usefulness of Real-Time 4D Ultrasonography during Radiofrequency Ablation in a Case of Hepatocellular Carcinoma |
Q44577619 | Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas |
Q90609144 | Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports |
Q34733478 | V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials |
Q30660492 | Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing |
Q41234297 | Validation of different staging systems for hepatocellular carcinoma in a cohort of 249 patients undergoing radiotherapy |
Q51674471 | Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver |
Q36715087 | Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma |
Q44088369 | Variant estrogen receptors and their role in liver disease. |
Q34559088 | Variation in the risk for liver and gallbladder cancers in socioeconomic and occupational groups in Sweden with etiological implications |
Q37564297 | Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature |
Q42418559 | Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI? |
Q35617324 | Viral hepatitis C. |
Q21245597 | Viral hepatitis and hepatocellular carcinoma |
Q34568619 | Viral hepatitis and liver cancer: the case of hepatitis C. |
Q37281965 | Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. |
Q37216659 | Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival |
Q35122983 | What surgeons should know about viral hepatitis and hepatocellular carcinoma |
Q36388315 | Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention |
Q34618851 | [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma |
Q52922062 | [HCC screening]. |
Q53466302 | [Imaging nodules within cirrhotic liver: how do I do it?]. |
Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
Q80052042 | [Palliative treatment of hepatocellular carcinoma] |
Q53225138 | [Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma]. |
Q74222020 | [Radiofrequency in the treatment of hepatocellular carcinoma] |
Q53526177 | [Should we screen for hepatocellular carcinoma?]. |
Q82526787 | [Surgery of hepatobiliary tumors] |
Q40553724 | alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses |
Q40733600 | gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin |
Q34790217 | miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14. |
Search more.